Hepatitis C virus infection, age, and hispanic ethnicity increase mortality from liver cancer in the United States

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 8, 2010, Pages 718-723

  Younossi, Zobair M ^a,b   Stepanova, Maria ^a,b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

Hepatocelluar Carcinoma; Liver Neoplasm; Liver Related Mortality

Indexed keywords

ALCOHOL; HEPATITIS B SURFACE ANTIGEN; IRON; VIRUS RNA;

ADOLESCENT; ADULT; AGE; ARTICLE; CANCER MORTALITY; CHRONIC LIVER DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; ETHNICITY; FEMALE; FOLLOW UP; HEPATITIS C; HISPANIC; HUMAN; IRON OVERLOAD; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; AGED; COMPLICATION; ETHNIC GROUP; FATTY LIVER; HEPATITIS B; LIVER TUMOR; MIDDLE AGED; MORTALITY; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ETHNIC GROUPS; FATTY LIVER; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HISPANIC AMERICANS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; UNITED STATES; YOUNG ADULT;

EID: 77955277833     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.04.017     Document Type: Article

References (24)

1. El-Serag H.B., Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750.
2. Edwards B.K., Ward E., Kohler B.A., et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010, 116:544-573.
3. Parken D.M. Global cancer statistics in the year 2000. The Lancet Oncology 2001, 2:533.
4. EL-Serag H.B., Rudolph L.K. Reviews in basic and clinical gastroenterology, hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
5. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
6. McGlynn K.A., Tsao L., Hsing A.W., et al. International trends and patterns of primary liver cancer. Int J Cancer 2001, 94:290-296.
7. McGlynn K.A., Tarone R.E., El-Serag H.B. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarker Prev 2006, 15:1198-1203.
8. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127:S27-S34.
9. Llovet J.M., Di Bisceglie A.M., Bruix J., et al. Design and endpoints of clinical trial in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711.
10. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
11. Davila J.A., Morgan R.O., Shaib Y., et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004, 127:1372-1380.
12. El-Serag H.B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002, 36:S74-S83.
13. Snowberger N., Chinnakotla S., Lepe R.M., et al. Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol Ther 2007, 26:1187-1194.
14. Surveillance, Epidemiology, and End Results (SEER) Program Public-Use CD-ROM (1973-1996) 1999, National Cancer Institute, National Cancer Institute, DCPC Surveillance Program, Cancer Statistics Branch, Bethesda, MD.
15. Analytic and reporting guidelines: the Third National Health and Nutrition Examination Survey, NHANES III (1988-94) 1996, CDC/NCHS, Hyattsville, MD.
16. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
17. International Classification of Diseases, Ninth (ICD-9) and Tenth (ICD-10) revisions WHO website, Accessed February 12, 2010. http://apps.who.int/classifications/apps/icd/icd10online/.
18. Leykum L.K., El-Serag H.B., Cornell J., et al. Screening for hepatocellular carcinoma among veterans with hepatitis C on diseases stage, treatment received, and survival. Clin Gastroenterol Hepatol 2007, 5:508-512.
19. El-Serag H.B., Lau M., Eschbach K., et al. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med 2007, 167:1983.
20. Davila J.A., El-Serag H.B. Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study. Clin Gastroenterol Hepatol 2006, 4:104-110.
21. El-Serag H.B., Marrero J.A., Rudolph L., et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008, 134:1752-1763.
22. Kanwal F., El-Serag H.B. Hepatocellular cancer care. Cost is important but only one factor of disease burden. J Hepatol 2009, 50:10-12.
23. Hickman I.J., Macdonald G.A. Impact of diabetes on the severity of liver disease. Am J Med 2007, 120:829-834.
24. Younossi Z.M., Gramlich T., Matteoni C.A., et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004, 2:262-265.